Literature DB >> 23576681

GARP-TGF-β complexes negatively regulate regulatory T cell development and maintenance of peripheral CD4+ T cells in vivo.

Angela X Zhou1, Lina Kozhaya, Hodaka Fujii, Derya Unutmaz.   

Abstract

The role of surface-bound TGF-β on regulatory T cells (Tregs) and the mechanisms that mediate its functions are not well defined. We recently identified a cell-surface molecule called Glycoprotein A Repetitions Predominant (GARP), which is expressed specifically on activated Tregs and was found to bind latent TGF-β and mediate a portion of Treg suppressive activity in vitro. In this article, we address the role of GARP in regulating Treg and conventional T cell development and immune suppression in vivo using a transgenic mouse expressing GARP on all T cells. We found that, despite forced expression of GARP on all T cells, stimulation through the TCR was required for efficient localization of GARP to the cell surface. In addition, IL-2 signals enhanced GARP cell surface expression specifically on Tregs. GARP-transgenic CD4(+) T cells and Tregs, especially those expressing higher levels of GARP, were significantly reduced in the periphery. Mature Tregs, but not conventional CD4(+) T cells, were also reduced in the thymus. CD4(+) T cell reduction was more pronounced within the effector/memory subset, especially as the mouse aged. In addition, GARP-overexpressing CD4(+) T cells stimulated through the TCR displayed reduced proliferative capacity, which was restored by inhibiting TGF-β signaling. Furthermore, inhibiting TGF-β signals greatly enhanced surface expression of GARP on Tregs and blocked the induction of Foxp3 in activated CD4(+) T cells overexpressing GARP. These findings suggest a role for GARP in natural and induced Treg development through activation of bound latent TGF-β and signaling, which negatively regulates GARP expression on Tregs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23576681      PMCID: PMC3653571          DOI: 10.4049/jimmunol.1300065

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Authors:  Paul A Antony; Ciriaco A Piccirillo; Akgül Akpinarli; Steven E Finkelstein; Paul J Speiss; Deborah R Surman; Douglas C Palmer; Chi-Chao Chan; Christopher A Klebanoff; Willem W Overwijk; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Immunol       Date:  2005-03-01       Impact factor: 5.422

Review 2.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

3.  Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo.

Authors:  Mei-Ling Chen; Mikaël J Pittet; Leonid Gorelik; Richard A Flavell; Ralph Weissleder; Harald von Boehmer; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

4.  The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.

Authors:  J S Munger; X Huang; H Kawakatsu; M J Griffiths; S L Dalton; J Wu; J F Pittet; N Kaminski; C Garat; M A Matthay; D B Rifkin; D Sheppard
Journal:  Cell       Date:  1999-02-05       Impact factor: 41.582

5.  Specific arrest of spermatogenesis caused by apoptotic cell death in transgenic mice.

Authors:  M Suzuki; K Abe; K Yoshinaga; M Obinata; M Furusawa; K Abe
Journal:  Genes Cells       Date:  1996-12       Impact factor: 1.891

6.  Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice.

Authors:  T Zhumabekov; P Corbella; M Tolaini; D Kioussis
Journal:  J Immunol Methods       Date:  1995-09-11       Impact factor: 2.303

7.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.

Authors:  K Inaba; M Inaba; N Romani; H Aya; M Deguchi; S Ikehara; S Muramatsu; R M Steinman
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

8.  T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells.

Authors:  Linda Fahlén; Simon Read; Leonid Gorelik; Stephen D Hurst; Robert L Coffman; Richard A Flavell; Fiona Powrie
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

9.  Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.

Authors:  Mary Jo Turk; José A Guevara-Patiño; Gabrielle A Rizzuto; Manuel E Engelhorn; Shimon Sakaguchi; Alan N Houghton
Journal:  J Exp Med       Date:  2004-09-20       Impact factor: 14.307

10.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.

Authors:  J H Kehrl; L M Wakefield; A B Roberts; S Jakowlew; M Alvarez-Mon; R Derynck; M B Sporn; A S Fauci
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

View more
  16 in total

1.  Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells.

Authors:  H Tanaka; W Zhang; G-X Yang; Y Ando; T Tomiyama; K Tsuneyama; P Leung; R L Coppel; A A Ansari; Z X Lian; W M Ridgway; T Joh; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2014-11       Impact factor: 4.330

2.  B lymphocytes confer immune tolerance via cell surface GARP-TGF-β complex.

Authors:  Caroline H Wallace; Bill X Wu; Mohammad Salem; Ephraim A Ansa-Addo; Alessandra Metelli; Shaoli Sun; Gary Gilkeson; Mark J Shlomchik; Bei Liu; Zihai Li
Journal:  JCI Insight       Date:  2018-04-05

3.  FOXP3+Helios+ Regulatory T Cells, Immune Activation, and Advancing Disease in HIV-Infected Children.

Authors:  Alka Khaitan; Adam Kravietz; Mussa Mwamzuka; Fatma Marshed; Tiina Ilmet; Swalehe Said; Aabid Ahmed; William Borkowsky; Derya Unutmaz
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-15       Impact factor: 3.731

4.  Atorvastatin Improves Inflammatory Response in Atherosclerosis by Upregulating the Expression of GARP.

Authors:  Xiaoqi Zhao; Yuzhou Liu; Yucheng Zhong; Bo Liu; Kunwu Yu; Huairui Shi; Ruirui Zhu; Kai Meng; Wei Zhang; Bangwei Wu; Qiutang Zeng
Journal:  Mediators Inflamm       Date:  2015-05-10       Impact factor: 4.711

5.  Mesenchymal stromal cells express GARP/LRRC32 on their surface: effects on their biology and immunomodulatory capacity.

Authors:  Ana Belén Carrillo-Galvez; Marién Cobo; Sara Cuevas-Ocaña; Alejandra Gutiérrez-Guerrero; Almudena Sánchez-Gilabert; Pierpaolo Bongarzone; Angélica García-Pérez; Pilar Muñoz; Karim Benabdellah; Miguel G Toscano; Francisco Martín; Per Anderson
Journal:  Stem Cells       Date:  2015-01       Impact factor: 6.277

Review 6.  The role of regulatory T cells in cancer immunology.

Authors:  Theresa L Whiteside
Journal:  Immunotargets Ther       Date:  2015-08-05

7.  Role of NF-kappaB2-p100 in regulatory T cell homeostasis and activation.

Authors:  Atika Dhar; Meenakshi Chawla; Somdeb Chattopadhyay; Neelam Oswal; Danish Umar; Suman Gupta; Vineeta Bal; Satyajit Rath; Anna George; G Aneeshkumar Arimbasseri; Soumen Basak
Journal:  Sci Rep       Date:  2019-09-25       Impact factor: 4.379

8.  Peripheral and thymic foxp3(+) regulatory T cells in search of origin, distinction, and function.

Authors:  Chetan Dhamne; Yeonseok Chung; Amin Majid Alousi; Laurence J N Cooper; Dat Quoc Tran
Journal:  Front Immunol       Date:  2013-08-27       Impact factor: 7.561

9.  Atopic dermatitis induces the expansion of thymus-derived regulatory T cells exhibiting a Th2-like phenotype in mice.

Authors:  Verena Moosbrugger-Martinz; Christoph H Tripp; Björn E Clausen; Matthias Schmuth; Sandrine Dubrac
Journal:  J Cell Mol Med       Date:  2016-03-02       Impact factor: 5.310

Review 10.  GARP: a surface molecule of regulatory T cells that is involved in the regulatory function and TGF-β releasing.

Authors:  Liping Sun; Hao Jin; Hui Li
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.